This site is intended for healthcare professionals only
LoginRegister
Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance FailuresUSFDA issues 15 observations for Jubilant HollisterStier General Partnership Montreal facility
RocheCDSCO Panel Rejects Roche Products India local Phase III CT waiver proposal for Atezolizumab...
CDSCO Panel Flags Ethnic Variability, Seeks More Data from Takeda for Fruquintinib Hard Capsule ApprovalTakeda announces Phase 3 topline results for Soticlestat in patients with Dravet Syndrome,...
Abhayrab Safe via Authorised Channels, Clarifies Indian Immunologicals Amid Fake Vaccine AlertsMerck Capvaxive gets USFDA nod for prevention of Invasive Pneumococcal Disease, Pneumococcal...
Lupin ropes in Abdelaziz Toumi as CEO of its API CDMO SubsidiaryLupin ropes in Abdelaziz Toumi as CEO of its API CDMO Subsidiary
USFDA Approves Bionpharmas Generic HIV Drug EtravirineUSFDA approves Merck Keytruda plus Carboplatin, Paclitaxel for Primary Advanced or Recurrent...
CDSCO Flags 7 Batches of Popular Medicines as Purportedly Spurious in DecemberCDSCO declares 5 formulations as spurious: Details
USFDA approves Alembic Pharma Icatibant Injection for acute attacks of hereditary angioedemaUSFDA approves Alembic Pharma Icatibant Injection for acute attacks of hereditary angioedema
Himachal CM ensures State financial backing for bulk drug park project alongside Central aid to ensure timely completionHimachal CM ensures State financial backing for bulk drug park project alongside Central aid to...
AbbVie Loses India Patent Bid for Cancer Drug Venetoclax, Generics Set to Enter MarketAbbVie, FutureGen ink pact to develop Next-Generation Therapy for Inflammatory Bowel Disease
CDSCO Clears AstraZenecas Imfinzi (Durvalumab) for Additional Cancer Indication in IndiaAstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or...
Intas PharmaDemonstrate safety and adequacy of dose: CDSCO Panel Tells Intas Pharmaceuticals on Bevacizumab...
X